

Rita Banzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3454207/publications.pdf>

Version: 2024-02-01

94
papers

3,861
citations

230014

27
h-index

150775

59
g-index

101
all docs

101
docs citations

101
times ranked

6780
citing authors

#	ARTICLE	IF	CITATIONS
1	Kappa and AC1/2 statistics: beyond the paradox. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 328-329.	2.4	2
2	Interventions for the management of transient tachypnoea of the newborn - an overview of systematic reviews. <i>The Cochrane Library</i> , 2022, 2022, CD013563.	1.5	6
3	High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries. <i>Travel Medicine and Infectious Disease</i> , 2022, 48, 102321.	1.5	6
4	Study designs for clinical trials applied to personalised medicine: a scoping review. <i>BMJ Open</i> , 2022, 12, e052926.	0.8	11
5	Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi. <i>Tumori</i> , 2021, 107, 91-94.	0.6	11
6	Long-Term Follow-Up of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: Aims and Methodological Approach for Fondazione Italiana Linfomi Systematic Reviews. <i>Cancers</i> , 2021, 13, 2976.	1.7	5
7	Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review. <i>BMJ Open</i> , 2021, 11, e053674.	0.8	23
8	Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 194-200.	1.2	21
9	Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 170-174.	1.1	16
10	Clinical evidence supporting the marketing authorization of biosimilars in Europe. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 557-566.	0.8	6
11	Sedative Load in Community-Dwelling Older Adults with Mild to Moderate Alzheimer's Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls. <i>Drugs and Aging</i> , 2020, 37, 829-837.	1.3	5
12	Interventions for the management of transient tachypnoea of the newborn - an overview of systematic reviews. <i>The Cochrane Library</i> , 2020, , .	1.5	1
13	The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. <i>Journal of Clinical Epidemiology</i> , 2020, 126, 37-44.	2.4	139
14	First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 2723-2735.	2.5	67
15	Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: data from NILVAD. <i>BMC Geriatrics</i> , 2020, 20, 117.	1.1	23
16	Assessment of a demonstrator repository for individual clinical trial data built upon DSpace. <i>F1000Research</i> , 2020, 9, 311.	0.8	1
17	Assessment of a demonstrator repository for individual clinical trial data built upon DSpace. <i>F1000Research</i> , 2020, 9, 311.	0.8	0
18	Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. <i>The Cochrane Library</i> , 2019, 2019, CD002919.	1.5	24

#	ARTICLE	IF	CITATIONS
19	Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. The Cochrane Library, 2019, 2019, CD011681.	1.5	28
20	New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. Journal of Clinical and Experimental Hepatology, 2019, 9, 522-538.	0.4	38
21	Looking for safety but overlooking efficacy: Non-inferiority trials of anti-diabetics. European Journal of Internal Medicine, 2019, 67, e9-e10.	1.0	0
22	Blood Pressure Lowering With Nilvadipine in Patients With Mild to Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. Journal of the American Heart Association, 2019, 8, e011938.	1.6	10
23	Risk of bias in nonrandomized studies of interventions showed low inter-rater reliability and challenges in its application. Journal of Clinical Epidemiology, 2019, 112, 28-35.	2.4	19
24	Evaluation of repositories for sharing individual-participant data from clinical studies. Trials, 2019, 20, 169.	0.7	36
25	Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Medicine, 2019, 17, 67.	2.3	72
26	Sharing individual participant data from clinical studies: a cross-sectional online survey among Italian patient and citizen groups. BMJ Open, 2019, 9, e024863.	0.8	13
27	Effectiveness of a Hospital-Based Computerized Decision Support System on Clinician Recommendations and Patient Outcomes. JAMA Network Open, 2019, 2, e1917094.	2.8	35
28	Cannabis as a medicine. An update of the Italian reality. European Journal of Internal Medicine, 2019, 60, e9-e10.	1.0	5
29	E-learning for health professionals. The Cochrane Library, 2018, 2018, CD011736.	1.5	196
30	Preapproval and postapproval evidence on drugs for multiple sclerosis. Neurology, 2018, 90, 964-973.	1.5	14
31	Quality assessment versus risk of bias in systematic reviews: AMSTAR and ROBIS had similar reliability but differed in their construct and applicability. Journal of Clinical Epidemiology, 2018, 99, 24-32.	2.4	63
32	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Medicine, 2018, 15, e1002660.	3.9	131
33	Regulatory response to contaminated valsartan. BMJ: British Medical Journal, 2018, 362, k3855.	2.4	6
34	Classification of processes involved in sharing individual participant data from clinical trials. F1000Research, 2018, 7, 138.	0.8	10
35	Classification of processes involved in sharing individual participant data from clinical trials. F1000Research, 2018, 7, 138.	0.8	13
36	Conditional approval of medicines by the EMA. BMJ: British Medical Journal, 2017, 357, j2062.	2.4	20

#	ARTICLE	IF	CITATIONS
37	Pharmacological pain and sedation interventions for the prevention of intraventricular hemorrhage in preterm infants on assisted ventilation - an overview of systematic reviews. The Cochrane Library, 2017, , .	1.5	5
38	Clinical research on rare diseases of children: neuroblastoma. Cancer Chemotherapy and Pharmacology, 2017, 79, 267-273.	1.1	2
39	Sharing and reuse of individual participant data from clinical trials: principles and recommendations. BMJ Open, 2017, 7, e018647.	0.8	116
40	A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?. Trials, 2017, 18, 556.	0.7	61
41	Klinička praksa temeljena na dokazima: pregled prijetnji valjanosti dokaza i kako ih spriječiti. Medicina Fluminensis, 2017, 53, .	0.1	0
42	Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants. The Cochrane Library, 2016, 2016, CD011636.	1.5	4
43	Patient-reported outcomes: nothing without engagement. Acta Oncologica, 2016, 55, 1494-1495.	0.8	1
44	Quality of reporting of diagnostic test accuracy studies in medical laboratory journals. Clinical Chemistry and Laboratory Medicine, 2016, 54, e319-e321.	1.4	2
45	Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine, 2016, 32, 13-21.	1.0	88
46	Heparin for the prevention of intraventricular haemorrhage in preterm infants. The Cochrane Library, 2016, 2016, CD011718.	1.5	6
47	Older patients are still under-represented in clinical trials of Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 32.	3.0	44
48	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. BMJ Open, 2016, 6, e011584.	0.8	21
49	Implementing an evidence-based computerized decision support system linked to electronic health records to improve care for cancer patients: the ONCO-CODES study protocol for a randomized controlled trial. Implementation Science, 2016, 11, 153.	2.5	16
50	IMPACT Observatory: tracking the evolution of clinical trial data sharing and research integrity. Biochimica Medica, 2016, 26, 308-317.	1.2	8
51	Providing Doctors With High-Quality Information: An Updated Evaluation of Web-Based Point-of-Care Information Summaries. Journal of Medical Internet Research, 2016, 18, e15.	2.1	59
52	E-learning for health professionals. The Cochrane Library, 2015, , .	1.5	6
53	Implementing an evidence-based computerized decision support system to improve patient care in a general hospital: the CODES study protocol for a randomized controlled trial. Implementation Science, 2015, 11, 89.	2.5	15
54	Telerehabilitation and recovery of motor function: a systematic review and meta-analysis. Journal of Telemedicine and Telecare, 2015, 21, 202-213.	1.4	196

#	ARTICLE	IF	CITATIONS
55	EMA and national drug agencies: cooperation or competition?. <i>Revista Clinica Espanola</i> , 2015, 215, 221-223.	0.2	0
56	Approvals of drugs with uncertain benefitâ€“risk profiles in Europe. <i>European Journal of Internal Medicine</i> , 2015, 26, 572-584.	1.0	76
57	Fostering EMA's transparency policy. <i>European Journal of Internal Medicine</i> , 2014, 25, 681-684.	1.0	9
58	EMA's transparency seems to be opaque. <i>Lancet, The</i> , 2014, 384, 1847.	6.3	6
59	Constraint-induced movement therapy: trial sequential analysis applied to Cochrane collaboration systematic review results. <i>Trials</i> , 2014, 15, 512.	0.7	6
60	Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. <i>Lancet Oncology, The</i> , 2014, 15, 172-183.	5.1	508
61	Homeopathy cannot even be used to replace placebo. <i>European Journal of Internal Medicine</i> , 2014, 25, e68.	1.0	1
62	NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. <i>BMJ Open</i> , 2014, 4, e006364.	0.8	47
63	Placebo? no thanks, it might be bad for me!. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 711-714.	0.8	19
64	Highâ€“risk HPV testing on selfâ€“sampled <i>versus</i> clinicianâ€“collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. <i>International Journal of Cancer</i> , 2013, 132, 2223-2236.	2.3	210
65	European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication. <i>Endoscopy</i> , 2012, 45, 51-59.	1.0	356
66	Informed consent: meet patients' needs. <i>Nature</i> , 2012, 483, 36-36.	13.7	1
67	Comparing participation rates between immunochemical and guaiac faecal occult blood tests: A systematic review and meta-analysis. <i>Preventive Medicine</i> , 2012, 55, 87-92.	1.6	112
68	Multiple systematic reviews: methods for assessing discordances of results. <i>Internal and Emergency Medicine</i> , 2012, 7, 563-568.	1.0	23
69	EMAâ€™s reflection on placebo does not reflect patientsâ€™ interests. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 877-879.	0.8	12
70	Antibiotics versus surgery for appendicitis. <i>Lancet, The</i> , 2011, 378, 1067-1068.	6.3	2
71	Navigators for medicine: evolution of online point-of-care evidence-based services. <i>International Journal of Clinical Practice</i> , 2011, 65, 6-11.	0.8	22
72	Review of â€œpullâ€“point-of-care services. <i>International Journal of Medical Informatics</i> , 2011, 80, 604-605.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Conceptual frameworks and empirical approaches used to assess the impact of health research: an overview of reviews. <i>Health Research Policy and Systems</i> , 2011, 9, 26.	1.1	110
74	Speed of updating online evidence based point of care summaries: prospective cohort analysis. <i>BMJ: British Medical Journal</i> , 2011, 343, d5856-d5856.	2.4	52
75	A Review of Online Evidence-based Practice Point-of-Care Information Summary Providers. <i>Journal of Medical Internet Research</i> , 2010, 12, e26.	2.1	60
76	Utilities and QALYs in health economic evaluations: glossary and introduction. <i>Internal and Emergency Medicine</i> , 2010, 5, 349-352.	1.0	8
77	Review of Online Evidence-based Practice Point-of-Care Information Summary Providers: Authors'™ Reply to the Response by the Publisher of DynaMed. <i>Journal of Medical Internet Research</i> , 2010, 12, e40.	2.1	0
78	Internet-Based Education for Health Professionals. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 598.	3.8	2
79	Measuring the impact of evidence: the Cochrane systematic review of organised stroke care. <i>Internal and Emergency Medicine</i> , 2009, 4, 507-510.	1.0	13
80	Rimonabant for overweight and "metabolic syndrome": the attempt to supersize disease and risk by pharmaceutical marketing. <i>Internal and Emergency Medicine</i> , 2008, 3, 53-56.	1.0	1
81	Novel Class of Quinone-Bearing Polyamines as Multi-Target-Directed Ligands To Combat Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4882-4897.	2.9	125
82	Haematological anticancer drugs in Europe: any added value at the time of approval?. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 713-719.	0.8	17
83	Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. <i>International Clinical Psychopharmacology</i> , 2006, 21, 319-336.	0.9	84
84	3-(2-Aminoethyl)pyridine analogs as α 2 nicotinic cholinergic receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4308-4312.	1.0	7
85	Propidium-Based Polyamine Ligands as Potent Inhibitors of Acetylcholinesterase and Acetylcholinesterase-Induced Amyloid- β Aggregation. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 24-27.	2.9	137
86	Polyamines May Modulate Both G Protein-Coupled Receptors and G Proteins. <i>Medicinal Chemistry Research</i> , 2004, 13, 63-73.	1.1	1
87	Design, Synthesis and Biological Evaluation of Ambenonium Derivatives as AChE Inhibitors.. <i>ChemInform</i> , 2004, 35, no.	0.1	0
88	Structure-Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 3. Effect of Replacing the Inner Polymethylene Chain with Cyclic Moieties. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6490-6498.	2.9	32
89	Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. <i>Il Farmaco</i> , 2003, 58, 917-928.	0.9	10
90	Polymethylene tetraamine backbone as template for the development of biologically active polyamines. <i>Medicinal Research Reviews</i> , 2003, 23, 200-233.	5.0	21

#	ARTICLE	IF	CITATIONS
91	Polymethylene Tetraamine Backbone as Template for the Development of Biologically Active Polyamines. ChemInform, 2003, 34, no.	0.1	0
92	Structure-Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 2. Role of the Substituents on the Phenyl Ring and Nitrogen Atoms of Caproctamine. Journal of Medicinal Chemistry, 2003, 46, 954-966.	2.9	35
93	Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adults. The Cochrane Library, 0, , .	1.5	0
94	Deep brain stimulation of subthalamic nucleus for Parkinson's disease. The Cochrane Library, 0, , .	1.5	0